Mechanistic studies confirmed that Bcl9@TP competitively disrupts β-catenin/BCL9 interactions, destabilizes the β-catenin/TCF transcriptional complex, and inhibits aberrant Wnt signaling activation, thereby suppressing tumor growth. Here, BCL9 is linked to neoplasm.